[en] Activation of the matrix metalloproteinase 2 (MMP-2) has been shown to play a major role in the proteolysis of extracellular matrix (ECM) associated with tumor invasion. Although the precise mechanism of this activation remains elusive, levels of the membrane type 1-MMP (MT1-MMP) at the cell surface and of the tissue inhibitor of MMP-2 (TIMP-2) appear to be two important determinants. Induction of MMP-2 activation in cells cultivated on collagen type I gels indicated that the ECM is important in the regulation of this process. In this study, we show that SPARC/osteonectin, a small ECM-associated matricellular glycoprotein, can induce MMP-2 activation in two invasive breast cancer cell lines (MDA-MB-231 and BT549) but not in a noninvasive counterpart (MCF-7), which lacks MT1-MMP. Using a set of peptides from different regions of SPARC, we found that peptide 1.1 (corresponding to the NH2-terminal region of the protein) contained the activity that induced MMP-2 activation. Despite the requirement for MT1-MMP, seen in MCF-7 cells transfected with MT1-MMP, the activation of MMP-2 by SPARC peptide 1.1 was not associated with increased steady-state levels of MT1-MMP mRNA or protein in either MT1-MMP-transfected MCF-7 cells or constitutively expressing MDA-MB-231 and BT549 cells. We did, however, detect decreased levels of TIMP-2 protein in the media of cells incubated with peptide 1.1 or recombinant SPARC; thus, the induction of MMP-2 activation by SPARC might be due in part to a diminution of TIMP-2 protein. We conclude that SPARC, and specifically its NH2-terminal domain, regulates the activation of MMP-2 at the cell surface and is therefore likely to contribute to the proteolytic pathways associated with tumor invasion.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Gilles, Christine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Bassuk, J. A.
Pulyaeva, H.
Sage, E. H.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Thompson, E. W.
Language :
English
Title :
SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines.
Publication date :
1998
Journal title :
Cancer Research
ISSN :
0008-5472
eISSN :
1538-7445
Publisher :
American Association for Cancer Research, Inc. (AACR), Baltimore, United States - Maryland
Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
Tournier, J. M., Polette, M., Hinnraski, J., Beck, J., Werb, Z., and Basbaum, C. Expression of gelatinase A, a mediator of extracellular matrix remodeling, by tracheal gland serous cells in culture and in vivo. J. Biol. Chem., 41: 25454-25464, 1994.
Aimes, R. T., and Quigley, J. P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyses the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem., 270: 5872-5876, 1995.
Strongin, A. Y., Marmer, B. L., Grant, G. A., and Goldberg, G. I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem., 268: 14033-14039, 1993.
Atkinson, S. J., Crabbe, T., Cowell, S., Ward, R. V., Butler, M. J., Sato, H., Seiki, M., Reynolds, J. J., and Murphy, G. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J. Biol. Chem., 270: 30479-30485, 1995.
Stetler-Stevenson, W. G. Progelatinase A activation during tumor cell invasion. Invasion Metastasis, 14: 259-268, 1994-95.
Nagase, H. Activation mechanisms of matrix metalloproteinases. Biol. Chem., 378: 151-160, 1997.
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature (Lond.), 370: 61-65, 1994.
Sato, H., and Seiki, M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J. Biochem., 119: 209-215, 1996.
Lohi, J., and Keski-Oja, J. Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J. Biol. Chem., 270: 17602-17609, 1995.
Yu, M., Sato, H., Seiki, M., and Thompson, E. W. Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res., 55: 3272-3277, 1995.
Lohi, J., Lehti, K., Westermark, J., Kähäri V-M., and Keski-Oja, J. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factor and phorbol 12-myristate 13-acetate. Eur. J. Biochem., 239: 239-247, 1996.
Pulyaeva, H., Bueno, J., Polette, M., Birembaut, P., Sato, H., Seiki, M., and Thompson, E. W. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin. Exp. Metastasis, 15: 111-120, 1997.
Ward, R. V., Atkinson, S. J., Slocombe, P. M., Docherty, A. J. P., Reynolds, J. J., and Murphy, G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72-kDa progelatinase by fibroblast membranes. Biochem. Biophys. Acta, 1079: 242-246, 1991.
Ward, R. V., Atkinson, S. J., Reynolds, J. J., and Murphy, G. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem. J., 304: 263-269, 1994.
Yu, A. E., Hewitt, R. E., Kleiner, D. E., and Stetler-Stevensen, W. G. Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem. Cell. Biol., 74: 823-831, 1996.
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem., 270: 5331-5338, 1995.
Sato, H., Takino, T., Kinoshita, T., Imai, K., Okada, Y., and Stetler-Stevenson, W. G. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase. FEBS Lett., 385: 238-240, 1996.
Sato, H., Kinoshita, T., Takino, T., Nakayama, K., and Seiki, M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinase (TIMP)-2. FEBS Lett., 393: 101-104, 1996.
Polette, M., and Birembaut, P. Matrix metalloproteinases in breast cancer. Breast J., 2: 209-220, 1996.
Crawford, H. C., and Matrisian, L. M. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis, 14: 234-245, 1994-1995.
McDougall, J. R., and Matrisian, L. Contribution of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
Gilles, C., Polette, M., Piette, J., Munaut, C., Thompson, E. W., Birembaut, P., and Foidart, J. M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer, 65: 209-213, 1996.
Gilles, C., Polette, M., Seiki, M., Birembaut, P., and Thompson, E. W. Implication of collagen type I-induced membrane-type I-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab. Invest., 76: 651-660, 1997.
Polette, M., Gilles, C., de Bentzmann, S., Gruenert, D., Tournier, J. M., and Birembaut, P. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin. Exp. Metastasis, 16: 105-112, 1998.
Azzam, H. S., and Thompson, E. W. Collagen-induced activation of the Mr 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res., 52: 4540-4544, 1992.
Seltzer, J. L., Lee, A., Akers, K. T., Sudbeck, B., Southon, E. A., Wayner, E. A., and Eisen, A. Z. Activation of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp. Cell Res., 213: 365-374, 1994.
Lee, A. Y., Akers, K. T., Collier, M., Li, L., Eisen, A. Z., and Seltzer, J. L. Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc. Natl. Acad. Sci. USA, 94: 4424-4429, 1997.
Tomasek, J. J., Halliday, N. L., Updike, D. L., Ahern-Moore, J. S., Vu, T. K., Liu, R. W., and Howard, E. W. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J. Biol. Chem., 272: 7482-7487, 1997.
Haas, T. L., Davis, S. J., and Madri, J. A. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J. Biol. Chem., 273: 3604-3610, 1998.
Bornstein, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol., 130: 503-506, 1995.
Sage, E. H. Terms of attachment: SPARC and tumorigenesis. Nat. Med., 3: 171-176, 1997.
Tremble, P. M., Lane, T. F., Sage, E. H., and Werb, Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol., 121: 1433-1444, 1993.
Shankavaram, U. T., DeWitt, D. L., Funk, S. E., Sage, E. H., and Wahl, L. M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell. Physiol., 173: 327-334, 1997.
Bellahcène, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.
Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., and Gown, A. M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem., 43: 791-800, 1995.
Ledda, M. F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., and Podhajcer, O. L. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol., 108: 210-214, 1997.
Graham, J. D., Balleine, R. L., Milliken, J. S., Bilous, A. M., and Clarke, K. L. Expression of osteonectin mRNA in human breast tumors is inversely correlated with oestrogen receptor content. Eur. J. Cancer, 33: 1654-1660, 1997.
Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., Mordoh, J., and Podhajcer, O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3: 171-176, 1997.
Sommers, C. L., Byers, S. W., Thompson, E. W., Torri, J., and Gelmann, E. P. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat., 31: 325-335, 1994.
Bassuk, J. A., Baneyx, F., Vernon, R. B., Funk, S. E., and Sage, E. H. Expression of biologically active human SPARC in Escherichia coli. Arch. Biochem. Biophys., 325: 8-19, 1996.
Lane, T. F., and Sage, E. H. Functional mapping of SPARC: peptides from two distinct Ca++-binding sites modulate cell shape. J. Cell Biol., 111: 3065-3076, 1990.
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
DeClerck, Y. A., Yean, T. D., Lu, H. S., Ting, J., and Langley, K. E. Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J. Biol. Chem., 266: 3893-3899, 1991.
Noël, A., Hajitou, A., L'Hoir, C., Maquoi, E., Baramova, E., Lewalle, J. M., Remacle, A., Kebers, F., Brown, P., Calbercq-Bacq, C. M., and Foidart, J. M. Inhibition of stromal matrix metalloproteases: effects on breast tumor promotion by fibroblasts. Int. J. Cancer, in press, 1998.
Sage, H. Vernon, R. B., Funk, S. E., Everitt, E. A., and Angello, J. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca2+-dependent binding to the extracellular matrix. J. Cell Biol., 109: 341-356, 1989.
Lane, T. F., and Sage, E. H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J., 8: 163-173, 1994.
Sage, E. H., and Vernon, R. B. Regulation of angiogenesis by extracellular matrix: the growth and the glue. J. Hypertens., 12: S145-S152, 1994.
Sage, E. H., Bassuk, J. A., Yost, J. C., Folkman, M. J., and Lane, T. F. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca2+-binding EF-hand sequence. J. Cell. Biochem., 57: 127-140, 1995.
Strandjord, T. P., Sage, E. H., and Clark, J. G. SPARC participates in the branching morphogenesis of developing fetal rat lung. Am. J. Respir. Cell Mol. Biol., 13: 279-287, 1995.
Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., and Berkowitz, R. S. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12: 1895-1901, 1996.
Termine, J. D., Kleinman, H. K., Whitson, S. W., Conn, K. M., McGarvey, M. L., and Martin, G. R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell, 26: 99-105, 1981.
Sasaki, T., Göhring, W., Mann, K., Maurer, P., Hohenester, E., Knäuper, V., Murphy, G., and Timpl, R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem., 272: 9237-9243, 1997.
Azzam, H., Arrand, G. A., Lippman, M. E., and Thompson, E. W. MMP-2 activation potential associates with metastatic progression in human breast cancer cell lines and is independent of MMP-2 production. J. Natl. Cancer Inst., 85: 1758-1764, 1993.
Iruela-Arispe, M. L., Vernon, R. B., Wu, H., Jaenisch, R., and Sage, E. H. Type I collagen-deficient mov-13 mice do not retain SPARC in the extracellular matrix: implication for fibroblast function. Dev. Dyn., 207: 171-183, 1996.
Sage, E. H. Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol., 7: 182-186, 1997.
Mayer, U., Aumailley, M., Mann, K., Timpl, R., and Engel, J. Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. Eur. J. Biochem., 198: 141-150, 1991.
Nischt, R., Pottgiesser, J., Krieg, T., Mayer, U., Aumailley, M., and Timpl, R. Recombinant expression and properties of the human calcium-binding extracellular matrix protein BM-40. Eur. J. Biochem., 200: 529-536, 1991.
Pottgiesser, J., Maurer, P., Mayer, U., Nischt, R., Mann, K., Timpl, R., Krieg, T., and Engel, J. Changes in calcium and collagen IV binding caused by mutations in the EF hand and other domains of extracellular matrix protein BM-40 (SPARC, osteonectin). J. Mol. Biol., 238: 563-574, 1994.
Murphy-Ullrich, J. E., Lane, T. F. Pallero, M. A., and Sage, E. H. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca2+-binding EF-hand. J. Cell. Biochem., 57: 341-350, 1995.
Hohenester, E., Maurer, P., and Timpl, R. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J., 16: 3778-3786, 1997.
Ailenberg, M., and Silverman, M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP). Biochem. J., 313: 879-884, 1996.